Unknown Analyst
Welcome, everyone, to the JPMorgan Healthcare Conference. We are pleased to have with us the Almirall management team here with us today, Carlos Gallardo, Chairman and CEO; Karl Ziegelbauer, CFO; Jon Garay, CFO; and Pablo Divasson, Head of IR.
With that, we’ll let Carlos have the stage. For logistics purposes, please reserve your questions until the end of the presentation.
Carlos Gallardo Piqué
CEO, President, Member of Management Board & Chairman of the Board
Good evening, everyone, and thanks to JPM for inviting us one more year to present where we are in our journey towards leadership in medical dermatology. Here, I remind you of our disclaimers. I’m just going to spend a few seconds here, but it’s in the print out that we have posted on the website. In terms of agenda for today, I would like you to tell you about our growth story in dermatology, and the transformational opportunity that we have ahead of us with our pipeline, and I will close with some closing remarks.
For those of you that don’t know Almirall are not familiar with Almirall, let me spend just a few seconds. So it’s a European company based in Barcelona. It was founded 80 years ago. And in 2014, we took the strategic decision to focus exclusively on medical dermatology. Today, fast forward, we have already exceeded $1 billion in sales and more than 50% of those sales are already sales in medical dermatology. We have a solid base business and a very exciting dermatology growth engine, mainly driven by
